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Abstract: Advanced glycation end products (AGEs) are a heterogeneous, complex group 
of compounds that are formed when reducing sugar reacts in a non-enzymatic way with 
amino acids in proteins and other macromolecules. This occurs both exogenously (in food) 
and endogenously (in humans) with greater concentrations found in older adults. While 
higher AGEs occur in both healthy older adults and those with chronic diseases, research is 
progressing to both quantify AGEs in food and in people, and to identify mechanisms that 
would explain why some human tissues are damaged, and others are not. In the last twenty 
years, there has been increased evidence that AGEs could be implicated in the development 
of  chronic  degenerative  diseases  of  aging,  such  as  cardiovascular  disease,  Alzheimer’s 
disease and with complications of diabetes mellitus. Results of several studies in animal 
models  and  humans  show  that  the  restriction  of  dietary  AGEs  has  positive  effects  on 
wound  healing,  insulin  resistance  and  cardiovascular  diseases.  Recently,  the  effect  of 
restriction in AGEs intake has been reported to increase the lifespan in animal models. This 
paper will summarize the work that has been published for both food AGEs and in vivo 
AGEs and their relation with aging, as well as provide suggestions for future research. 
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1. Introduction  
Advanced glycation end products (AGEs) are a heterogeneous, complex group of compounds that 
are formed mainly via the Maillard reaction. The Maillard reaction occurs when reducing sugar reacts 
in a non-enzymatic way with amino acids in proteins, lipids or DNA. This reaction has been studied 
for years in the food industry because its products add a desirable color and taste to foods. However, 
the study of the products of this reaction in vivo have received increasing attention in recent years due 
to  association  of  AGEs  with  certain  chronic  diseases,  such  as  diabetes  mellitus,  cardiovascular 
diseases, and Alzheimer’s disease, as well as during the aging process. 
2. Formation of AGEs  
The formation of AGEs through the Maillard reaction occurs in three phases (Figure 1). First, 
glucose attaches to a free amino acid (mainly lysine and arginine) of a protein, lipid or DNA, in a 
non-enzymatic way to form a Schiff base. A Schiff base is a compound that has a carbon to nitrogen 
double bond where the nitrogen is not connected to hydrogen. The initiation of this first step depends 
on glucose concentration and takes place within hours. If the concentration of glucose decreases, this 
reaction is reversible. During the second phase, the Schiff base undergoes chemical rearrangement 
over  a  period  of days and  form Amadori products (also known  as early glycation products).  The 
Amadori products are more stable compounds (hemoglobin A1c is the most well known), but the 
reaction is still reversible. If there is accumulation of Amadori products, they will undergo complicated 
chemical rearrangements (oxidations, reductions, and hydrations) and form crosslinked proteins. This 
process takes place in weeks or months and it is irreversible. The final brownish products are called 
AGEs and some of them have fluorescent properties. They are very stable, and accumulate inside and 
outside  the  cells  and  interfere  with  protein  function  [1,2].  Besides  the  Maillard  reaction,  other 
pathways can also form AGEs. For instance, the autoxidation of glucose and the peroxidation of lipids 
into dicarbonyls derivatives by an increase in oxidative stress is another pathway described for the 
formation of AGEs [3]. These dicarbonyl derivatives known as α-oxaldehydes (glyoxal, methylglyoxal 
(MG), and 3-deoxyglucosone) can interact with monoacids and form AGEs. The other well-studied 
mechanism for the formation of AGEs is the polyol pathway, where glucose is converted to sorbitol by 
the enzyme aldose reductase and then to fructose by the action of sorbitol dehydrogenase. Fructose 
metabolites  (as  fructose  3-phosphate)  then  are  converted  into  α-oxaldehydes  and  interact  with 
monoacids to form AGEs [4]. Thus, at least three pathways may form AGEs: The Maillard reaction; 
oxidation of glucose; and peroxidation of lipids and through the polyol pathway. Given these differing 
pathways, it is not surprising that AGEs are diverse in their chemical structure. Among the most 
widely studied AGEs are carboxymethyl-lysine (CML), pentosidine, and pyrraline, and, together with 
methylglyoxal  (an  α-oxaldehyde),  they  have  been  used  as  biomarkers  for  in  vivo  formation  of 
AGEs [2,5,6]. CML (not fluorescent, not cross-linked AGEs) has been consistently used also as a 
biomarker  for  long-term  protein  damage  and  can  be  formed  by  the  Maillard  reaction  and  by 
α-oxaldehydes.  As  well  as  CML,  pentosidine  (a  fluorescent  protein  crosslink)  is  formed  by  the 
Maillard reaction and by the α-dicarbonyl glyoxal, while pyrraline (not fluorescent, not cross-linked 
AGEs) is formed by the Maillard reaction [7].  Nutrients 2010, 2  
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Figure 1. Formation of AGEs. 
 
The deleterious effects of AGEs in different tissues are attributed to their chemical, pro-oxidant, and 
inflammatory actions [1,2]. The biological effects of AGEs are exerted by two different mechanisms: 
One independent of the receptor (damage of protein structure and extracellular matrix metabolism); or 
one  involving  the  receptor  for  advanced  glycation  end  products  (RAGE)  [2,8]  (Figure  2).  The 
interaction of AGEs with the receptor RAGE triggers the activation of the mitogen-activated protein 
kinases  (MAPKs)  and  the  phosphatidylinositol-3  kinase  (PI3-K)  pathways  that  will  lead  to  the 
activation  of  the  transcription  factor  NF-B  (nuclear  factor  kappa  B).  After  activation,  NF-B 
translocates  to  the  nucleus  where  it  will  activate  the  transcription  of  genes  for  cytokines,  growth 
factors and adhesive molecules, such as tumor necrosis factor α (TNFα), interleukin 6 (Il-6), well 
known  inflammation  promoters,  and  vascular  cell  adhesion  molecule  1  (VCAM1)  [8-12].  NF-B 
activation increases RAGE expression, creating a positive feedback cycle that enhances the production 
of  inflammation  promoters.  In  addition,  AGE-RAGE  interaction  activates  NAD(P)H  oxidase 
(a complex of enzymes which produces superoxide) and when this complex is upregulated, it increases 
intracellular oxidative stress. The sudden increase in oxidative stress by NAD(P)H oxidase in response 
to AGE-RAGE interaction will also activate NF-B [13-15].  
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Figure 2. Mechanism of AGEs action at the cell level. 
 
3. Implications for Health 
Accumulation of AGEs has been found in healthy aging persons, and this accumulation is higher 
during high glucose concentrations. Microvascular and macrovascular damage, seen in diabetes, is 
attributed  to  the  accumulation  of  AGEs  in  tissues,  but  it  is  also  associated  with  atherosclerosis, 
Alzheimer’s disease, end stage renal  disease, rheumatoid  arthritis,  sarcopenia, cataracts, and  other 
degenerative ophthalmic diseases, Parkinson’s disease, vascular dementia and several other chronic 
diseases [16-19]. For instance, Bar et al. have demonstrated differential increases of AGEs products in 
Alzheimer’s dementia and vascular dementia compared to controls [20]. It has also been suggested that 
AGEs are involved in the loss of bone density and muscular mass associated with aging [21]. We 
discuss briefly some of the health implications described in the older population. 
3.1. Cardiovascular Diseases 
The in vivo accumulation of AGEs over time contributes to changes in the structure and function of 
the  cardiovascular  system  and  presents  as  arterial  stiffening,  myocardial  relaxation  abnormalities, 
atherosclerotic plaque formation and endothelial dysfunction. Several authors have described some of 
the mechanisms for these changes. One of the proposed mechanisms involves additional cross-linking 
on collagen (whose normal structure already contains crosslinking) by glycation of its free amino 
acids. The collagen-AGEs cross-linking will produce stiffness of blood vessels. Sims et al. completed 
a histological study on 27 samples of post-mortem aortas from people with diabetes and controls and 
found a correlation between AGEs accumulation and aortic stiffness [22]. Another mechanism by 
which AGEs exert damage to the cardiovascular system is reduction of low-density lipoproteins (LDL) 
uptake by cell receptors. This occurs through glycation of the LDL particle on the apolipoprotein B 
and in the phospholipid components of LDL. The glycated LDL is more susceptible to cross-linking 
with collagen on the arterial wall than non-glycated LDL, and it is not taken up into the cell and Nutrients 2010, 2  
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accumulates.  Macrophages  uptake  of  these  modified  LDL  lead  to  foam  cell  formation,  and  the 
development of atheroma [23,24]. Furthermore, decreasing in nitric oxide (NO) activity is another 
mechanism described by AGEs damaging the cardiovascular system. NO (a vasodilator) biosynthesis 
in the endothelium counteracts some of the mechanisms for atherosclerosis. Some authors proposed 
that AGEs reduce NO synthase (eNOS) half-life in the endothelium. For instance, Xu et al. found a 
decreased in eNOS activity after exposure to CML. They also found that after 30 minutes of exposure 
with CML-albumin, there was a reversible inhibition of endothelium and vascular response dependent 
on NO in vivo and in vitro [25-28].  
Additional work supports the role of increased androgens during and after menopause as a risk 
factor  for  cardiovascular  events  in  women,  with  an  associated  increase  in  AGEs.  A  study  of 
106 postmenopausal  women  found  significant  correlations  between  testosterone  and  free  androgen 
indices versus AGEs after adjustment for age, body mass index, insulin resistance indices, and fasting 
glucose and insulin levels [29]. 
Therefore, the accumulation of AGEs could be explained by some of the cardiovascular changes 
associated with aging, such as vascular stiffening, diastolic dysfunction and endothelial dysfunction [24]. 
A  study  with  long-term  (24–30  weeks)  administration  of  aminoguanidine  (an  inhibitor  of  AGE 
formation) showed prevention of the age-related cardiac hypertrophy and arterial stiffness [30]. It has 
also been found that CML, a predominant AGE, can serve as a predictor of cardiovascular mortality. 
Semba et al. studied a group of 559 women aged 65 and older for 4.5 years from the Women’s Health 
and  Aging  Study  I  (WHAS  I).  During  this  time  22%  of  the  population  died;  43.9%  from 
cardiovascular disease. They measured CML as a marker for AGEs and found that the highest risk for 
dying of cardiovascular disease were for women in the highest quartiles of CML [31]. From these 
reports, it appears that high concentrations of AGEs could be a risk factor for cardiovascular disease, 
but further evidence is needed to support this statement.  
3.2. Sarcopenia 
Loss of muscle mass and strength (sarcopenia) is a serious problem among older populations [32]. 
In accordance with recent studies, one third of women and half of men older than 60, have sarcopenia 
in the U.S. [33]. The pathogenesis of sarcopenia is multifactorial, and may include hormonal changes, 
increased oxidative stress and inflammation, changes in vasculature, and inactivity [34-36]. AGEs may 
also contribute to this condition by increasing oxidative stress and inflammation. Some studies have 
found a relation between AGEs and  muscular function in older population. Haus et al. found that 
pentosidine concentrations were 200% higher in a group of older individuals with a mean age of 78 y 
(n = 22) compared with their younger counterparts with a mean age of 25 y (n = 20). The authors 
concluded that  AGEs may contribute  to the decline of muscular function observed  in aging [37]. 
Dalal et al.  conducted  a  study  of  older  women  to  measure  the  AGEs  concentration  in  blood  and 
handgrip strength. Serum carboxymethyl-lysine (CML), the circulating soluble form of receptor for 
advanced glycation end products (sRAGE), endogenous secretory receptor for advanced glycation end 
product (esRAGE) and grip strength, were measured in 559 moderately-to-severely disabled women, 
age 65 and older, in the Women’s Health and Aging Study I in Baltimore. The authors found that 
women  with  higher  concentrations  of  CML  had  less  grip  strength  than  women  with  lower  CML Nutrients 2010, 2  
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concentrations. The authors concluded that women with higher AGEs have more muscle weakness [38]. 
These studies presented interesting results, but they are not conclusive of a causal relationship between 
AGEs  and  sarcopenia,  and  more  studies  will  need  to  further  address  this  health  problem  among 
older population.  
3.3. Renal Disease  
The relationship between renal disease and AGEs has largely been studied in patients with type 2 
diabetes mellitus, and to a lesser extent in older populations. Semba et al. [39] demonstrated that in an 
older  population  (n  =  1008),  elevated  circulating  AGEs  were  an  independent  predictor  of  renal 
function.  The  study  was  carried  out  in  men  and  women,  age  64  and  older,  participating  in  the 
InCHIANTI  study  in  Tuscany,  Italy.  The  results  of  the  study  demonstrated  an  elevated  plasma 
concentration  of  CML  independently  associated  with  chronic  kidney  disease  and  the  estimated 
glomerular filtration rate (an index of kidney function) at baseline, after three and six years of follow-
up. These findings suggest that the potential adverse effects of AGEs on the kidney are applicable to 
the general population of older community-dwelling adults [39]. In another study of 548 women from 
the Women’s Health and Aging Study I in Baltimore, 51.6% of women had decreased glomerular 
filtration rate, which was associated with increased serum levels of CML and sRAGE. However, more 
follow-up studies on the elderly population are needed to establish if high levels of CML could predict 
decreased in renal function [40]. 
3.4. Alzheimer’s Disease 
Although  a  definitive  etiology  for  Alzheimer’s  disease  is  unknown,  oxidative  stress  has  been 
identified as a primary risk factor for the disease. Both aging itself and the presence of AGEs are 
thought to be risk factors through their role in chemical, pro-oxidant, and inflammatory actions as 
previously described. A comparison of normal control and Alzheimer’s disease patients’ brain tissue 
found higher AGEs and RAGE expressions in age-matched controls [41]. In addition, there is evidence 
that RAGE mediates the blood-brain barrier transport of amyloid peptides in certain situations [42]. A 
recent review has described possible links between Alzheimer’s disease and diabetes, which include 
AGEs,  advancing  age,  as  well  as  oxidative  stress  and  hypercholesterolemia,  although  exact 
mechanisms and relationships require additional research [43].  
3.5. Diabetes 
Hemoglobin A1c is the most widely recognized early glycation product, and is also used as an 
indicator of blood glucose management in those with diabetes. Hyperglycemia increases the glycation 
process, and is especially apparent in insulin independent tissues such as red blood cells, peripheral 
nerve tissue cells, endothelial cells, eye lens cells, and kidney cells [44]. It is also hypothesized that 
glycation of proteolytic enzymes in diabetes reduces their efficiency, resulting in more build up of 
glycated  end  products  [44].  Not  surprisingly,  AGEs  have  also  been  implicated  in  delayed  wound 
healing associate with diabetes, presumably through vascular, neurological, or intermediary metabolic 
modifications [45]. Nutrients 2010, 2  
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4. Exogenous Sources of AGEs 
In addition to in vivo production, AGEs can also be found in cigarettes and in foods. The curing of 
tobacco leaves has been proposed as the source for compounds that can readily increase in vivo AGEs. 
Cerami et al. found that glycotoxins from cigarettes are inhaled into the alveoli, and then they are 
transported to blood stream or to lung cells where they can interact with other glycation products and 
contribute with AGEs formation [46].  
4.1. Dietary AGEs 
Heat has been used for treatment of foods to improve their safety, bioavailability and taste. In 
addition to these positive effects, overheating of foods can also provoke protein degradation and other 
deteriorative  reactions  [47].  Heat  treatment  in  some  foods  results  in  promotion  of  the  Maillard 
reaction, which adds desirable flavor, color and aroma. In the food industry, the Maillard reaction has 
been used for caramel production, coffee roasting, and bread baking among others. Some products of 
the Maillard reaction can be added to industrialized products such as sodas and juices among others [48]. 
There is growing evidence that the average Western diet is a plentiful source of exogenous AGEs. The 
AGEs content of a diet depends on the nutrient composition (foods rich in protein and fat have the 
highest content) and on the way food is processed [49,50]. AGEs formation can be rapidly accelerated 
by  increasing  the  time  and  degree  of  exposure  to  heat  and  can  be  introduced  into  the  body  in 
heat-processed  foods  [47,49,50].  These  findings  were  demonstrated  using  an  AGE-specific, 
enzyme-linked  immunosorbent  assay  (ELISA),  and  it  was  estimated  that  ≈10%  of  ingested 
immunoreactive AGEs are transported into circulation, two-thirds of which remain in the body, and are 
incorporated covalently in tissues. Only one third is excreted via the kidneys [51]. 
However, it has been controversial whether dietary AGEs are harmful to human health. One of the 
reasons for this controversy is that, as well as those found in vivo, Maillard reaction products formed in 
foods are heterogeneous and only a few have been characterized. Some of the products formed during 
this intricate reaction are furfurals, pyrralines and dicarbonyl compounds such as methylglyoxal. The 
products formed in the last reaction of this process are known as melanoidins in food science [52]. As 
mentioned before, regardless of the diversity of AGEs, CML has been reported as one of the most 
abundant in vivo and it was one of the first to be characterized in foods (milk and milk products). For 
this reason in most studies CML is chosen as a marker of AGEs in foods and in vivo [53]. 
Studies on the effects of AGEs from foods not only are limited to CML, but also to the melanoidins 
found in bread crust, bakery products and coffee. Some positive and negative effects of melanoidins 
have been studied. Ames et al. found that melanoidins increased the number of anaerobes, clostridia, 
and bifidobacteria in a culture of human fecal bacteria [54]. These results indicate that a mixture of 
melanoidins can stimulate growth of health-beneficial bacteria in the gut. Borrelli et al. found similar 
results showing that melanoidins from bread crust can promote growth of some bifidobacterias strains, 
indicating a possible potential prebiotic effect of bread crust melanoidins. Somoza et al. carried out a 
study in rats fed with malt and bread crust to measure the activity of chemopreventive enzymes such as 
glutathione-S-transferase (GST) and UDP glucuronyl-transferase (UDP-GT) [55]. The activity of GST 
in kidney increased by 18% on the group fed with bread crust, while UDP-GT in liver increased by 27%. 
The authors concluded that diet malt and dietary bread crust increased chemopreventive enzymes in rats.  Nutrients 2010, 2  
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On the other hand, several studies, mostly with CML and MG, have shown that the intake of dietary 
AGEs modifies circulating AGEs levels in human subjects and animals with or without diabetes or 
renal disease. In a study with 90 healthy subjects, Uribarri et al. estimated the amount of AGEs from 
three  days  food  records  using  a  database  with  the  AGEs  content  of  certain  foods.  They  found  a 
significant correlation between the ingested AGEs and the plasma levels. A subgroup was exposed to a 
dietary restriction of AGEs and their plasma levels decreased as well. These results are similar to 
previous reports on patients with diabetes and renal failure patients [56]. Those findings support the 
view that the intake of dietary AGEs is an important contributor to the body AGEs pool [56-60]. 
Besides the endogenously formed AGEs, dietary AGEs have also been shown to act as RAGE ligands 
and activate major signal transduction pathways in vitro [11,61,62]. Dietary AGEs, together with those 
made endogenously, could promote a systemic glycoxidant burden, oxidant stress and cell activation, 
which increases vulnerability of target tissues to injury [63,64]. 
4.2. Dietary AGEs Metabolism  
Several studies have focused on understanding the absorption, metabolism and excretion of dietary 
AGEs. Forster et al. carried out a study to try and understand the bioavailability and the kinetics of 
elimination of some Maillard products found on custard, pretzels and brewed coffee. They found that 
pretzel sticks are a rich source of pentosidine and pyrraline. The study was carried out with 18 healthy 
subjects who received specific amounts of these foods on a single day. Urinary excretion of pyrraline 
and pentosidine was measured by chromatographic methods for the following three days. The urinary 
excretion of both Maillard products increased after ingestion and the rate of recovery in urine was 
around  50%  for  pyrraline  and  around  60%  for  pentosidine.  However,  the  metabolic  fate  of  the 
pyrraline and pentosidine is unknown [65]. 
The mechanisms of intestinal absorption of AGEs are not yet well understood. A recent study trying 
to answer this question found that pyrraline is absorbed by the peptide transporter hPEPT1. This study 
is the first one addressing this question and studies on the absorption mechanism for more AGEs are 
needed [66]. 
A few studies about intestinal absorption of different AGEs have been conducted. However, the 
complete extent of absorption of each individual AGE is not well known. As mentioned before, the 
most studied dietary AGEs are CML, pyrraline and pentosidine. Several studies have shown different 
rates of absorption of each of them. However, their metabolic pathways have not been elucidated. 
More studies on this area are needed to understand the impact of dietary AGEs on health and aging. 
5. AGEs in the Elderly 
The serum levels of AGEs are dependant of endogenous production, exogenous intake and renal 
and enzymatic clearance, which together produce transient increases and decreases in serum AGEs 
levels. Several enzymes (glyoxalase I, II and carbonyl reductase) and a receptor (AGER1) have been 
shown to be part of a detoxification and counterregulation system against the prooxidant effects of 
glycation  [67,68].  In  addition,  renal  excretion  eliminates  excess  of  AGEs  production  under 
physiological conditions. Some authors have proposed that with aging as well as in some pathological 
conditions  there  is  imbalance  in  this  steady-state.  This  imbalance  can  be  due  to  an  increased Nutrients 2010, 2  
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endogenous production, or an increased exogenous intake that, in combination with lower renal AGEs 
clearance, leads to the accumulation of AGEs observed in older population [68,69].  
Uribarri  et  al.  investigated  whether  AGEs  intake  correlated  with  glycotoxin  levels,  markers  of 
inflammation and oxidative stress (OS) comparing older versus younger healthy adults. They studied 
172 healthy volunteers in two groups (18–45 years) and (60–80 years). The CML and MG derivatives 
were  higher  in  the  older  group.  The  concentration  of  AGEs  in  serum  correlated  with  levels  of 
inflammation markers and OS. Additionally, the level of dietary glycotoxins correlated independently 
with CML and MG derivatives, as well as hsCRP. The association found between sCML and the 
homeostasis model assessment (HOMA an instrument to measure insulin sensitivity) levels of normal 
persons  could  be  linked  to  metabolic  processes,  which  may  precede  insulin  resistance,  diabetes 
mellitus, or vascular dysfunction at any age [70]. Vlassara et al. found similar results in a study with 
325 healthy participants and 66 participants with kidney disease (CKD). Serum CML and MG were 
higher  in  the  group  of  older  participants,  and  serum  CML  correlated  negatively  with  eGFR  and 
positively with age [67]. 
The accumulation of AGEs in tissues may contribute to increased OS, and as a final result, impair 
organ  function  [16].  Indeed,  within  the  complex  the  association  between  OS  and  aging  ovarian 
follicles, AGEs may have an important role as they accumulate over the lifespan [71]. More recent 
work  suggests  a  mechanism  for  this  in  that  detoxification  of  an  AGEs  precursor  is  significantly 
diminished in older mice, allowing AGEs to increase [72]. Additionally, slowly diminishing renal 
function with age [73] could affect the ability to excrete AGEs. Uribarri et al. suggest this as a possible 
explanation as to why they found high AGE levels in the older group, even though the intake of dietary 
AGEs by the older age group was reduced [70]. More evidence is needed, but these results suggest the 
important  role  of  dietary  and  circulating  AGEs  in  chronic  degenerative  diseases,  which  are  more 
prevalent in the elderly. 
6. Strategies for AGEs Reduction  
Some  of  the  strategies  studied  to  lower  the  extra  load  of  AGEs  are  reducing  dietary  AGEs, 
pharmacological treatment and, more recently, exercise.  
6.1. Dietary Restriction of AGEs 
Findings in several intervention studies, both human subjects and animals, indicate that the high 
intake of dietary AGEs contributes to tissue damage that can be prevented by dietary AGEs restriction. 
These intervention studies reduced dietary AGEs by decreasing the heat during the preparation of 
foods  [74-79].  Sebekova  et  al.  found  that  long-term  consumption  of  AGEs  in  rats  leads  to  a 
dose-dependent increase in proteinuria that overtime could induce renal damage [80]. In addition, the 
high long term consumption of AGEs has also been associated to higher levels of fasting glucose, 
insulin and serum AGEs, as well as increased AGEs localization and RAGE staining in ovarian tissue 
of rats [81]. In studies of mice, reduced dietary AGEs have been found to attenuate insulin resistance, 
increase  the  prevention  of  diabetes  and,  in  diabetic  mice,  reduce  diabetic  vascular  and  renal 
complications, and improve impaired wound healing [74-76].  Nutrients 2010, 2  
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Whereas in human studies, Uribarri et al. demonstrated that intake of dietary AGEs by people with 
type  1  and  2  diabetes  promotes  the  formation  of  pro-inflammatory  mediators,  leading  to  tissue 
injury [82]. Patients with uremia, with and without diabetes, in whom the intake of AGEs was reduced, 
showed  reduced  levels  of  inflammatory  molecules  such  as  TNF-α  and  high  sensitivity  C-reactive 
protein (hsCRP) [79]. In another study in patients with type 2 diabetes mellitus, decreasing the intake 
of  AGEs  for  six  weeks  contributed  to  decreased  levels  of  circulating  AGEs  and  inflammatory 
markers [60]. The effects of reducing dietary AGEs have also been studied in nondiabetic peritoneal 
dialysis patients, a group that has very high AGE levels, and the results showed significant reduction in 
the levels of AGEs and C-reactive protein [79]. 
6.2. Role of Restriction of Dietary AGEs in Lifespan 
It has been demonstrated that caloric restriction increases lifespan in C. elegans and mice. Several 
centenarian  populations  have  been  studied,  and  they  have  one  thing  in  common:  a  lower  caloric 
intake [83,84]. It has been postulated that positive outcomes of caloric restriction (CR) in mice could 
be explained in part by a decrease in the intake of AGEs and concomitant decrease of OS [85]. 
To  investigate  whether  a  reduction  in  CR  would  decrease  the  AGE  intake,  and  whether  this 
decrease could explain the benefits of CR, investigators studied three groups of mice assigned to one 
of three diets (n = 22 per group): CR diet, regular diet; or CR diet high in AGEs [86]. A longer lifespan 
in CR mice versus Reg or CR-high mice (median and maximal survival 13.2% and 6%, respectively) 
was reported. Additionally, survival in CR-high mice was shorter than in Reg mice. There was a 
significant increase of OS in the CR-high group and accelerated aging-related cardiovascular and renal 
disease and a shorter lifespan. In these studies, the high levels of AGEs in the CR-high diet compete 
with the benefits of CR, but the mechanism remained uncertain [86].  
6.3. Exercise and AGEs 
Published reports of research linking exercise and AGEs are sparse. One of the first studies in this 
subject suggested a decrease in levels of AGEs in exercise-trained diabetic rats as compared with 
sedentary diabetic rats. A possible explanation for the decrease is that adaptation to systemic physical 
exercise in diabetic animals affects not only enzyme-regulated metabolism but also non-enzymatic 
processes involving protein glycation. This study was published in Russian, so access was only to the 
abstract.  Another  study  explored  whether  exercise  prevented  the  age-associated  changes  in 
non-enzymatic cross-linking of myocardial collagen, and thus may improve cardiac performance in an 
animal model. In this study long-term exercise training appeared to attenuate age-related deteriorations 
in cardiac contractility and myocardial stiffness and was related to decreases in myocardial pathologic 
collagen cross-linking (AGEs cross-linked collagen) in old rats (n = 7) when compared with controls 
(n = 7) [87]. Boor et al. carried out a study in Zucker rats where one group (n = 8) had a training 
program for five weeks and the other group (n = 8) did not perform any exercise. It was found that the 
group with the training protocol had lower levels of CML in plasma, renal cortex and in glomeruli, in 
comparison with the sedentary group [88].  
Few studies have explored the effects of exercise on AGEs on the human model. One of them 
showed the effect of Tai Chi in a healthy Malaysian population older than 45 years. The subjects were Nutrients 2010, 2  
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randomized either to practice Tai Chi two times per week or to a control group. Measures were taken 
at 0, 6, and 12 months. The subjects in the Tai Chi group had a decrease in concentration of AGEs and 
malondialdehyde MDA (a lipoxidation marker) after 12 months of intervention [89]. In another study, 
researchers reported the acute effect of exercise in subjects with coronary artery disease, finding no 
difference between the levels of RAGE before and after the training session [90]. Recently, Yoshikawa 
recruited seventeen healthy women (30–60 y) who participated in a lifestyle modification protocol for 
three months to measure changes in AGEs. The protocol aimed to increase physical activity among the 
intervention  group,  which  was  measured  by  a  pedometer.  An  education  session  was  given  at  the 
beginning of the study and participants attended supervised sessions once per week. Levels of CML 
decreased in the treatment group compared to the control group (n = 12) and CML decrease was 
negatively correlated with the number of daily steps [91].  
6.4. Pharmacological Interventions 
Several pharmacological agents have been studied as blockers of AGEs crosslinking or as blockers 
of their actions using cellular, animal and human models: benfotiamine (a B1-like vitamin with higher 
bioavailability), metformin, aminoguanidine, aspirin, and inhibitors of the renin-angiotensin system for 
example.  Saha  et  al.  showed  that  Candersatan,  an  angiotensin  receptor  blocker,  administered  for 
12 weeks  reduced  levels  of  CML  in  the  urine  of  patients  with  diabetic  kidney  disease  [92]. 
Aminoguanidine,  a  scavenger  of  α-dicarbonyl,  showed  in  some  studies  promising  results  as  an 
inhibitor of AGEs formation. However, a clinical trial carried out in diabetic patients was stopped due 
to  safety  concerns  and  lack  of  efficacy.  Patients  presented  secondary  effects  that  included 
gastrointestinal  disturbance,  abnormal  tests  for  liver  function,  and  flu-like  symptoms  [93]. 
Additionally, metformin has shown to decrease circulating AGEs in patients with diabetes, as well as 
decreasing the activity of NFB [94]. In a study of 22 women with polycystic ovary disease (PCOS), 
metformin therapy for six months resulted in a reduction of serum AGEs [95]. In a similar intervention 
with 21 women with PCOS, Orlistat, a lipase inhibitor, reduced serum AGEs after a high AGEs meal 
as compared to 15 women without PCOS by decreasing AGEs absorption [96]. A six month study 
evaluating the effect of calorie restriction and Orlistat found serum AGEs reduction in both the PCOS 
and  obese  groups,  independent  of  body  mass  index  changes  [97].  Some  of  these  agents  are  in 
preclinical or clinical phase trials, and it could be a long time before any of these treatments emerge as 
effective and safe therapeutic agents to inhibit and counteract AGEs effects. 
7. Limitations of Dietary AGEs Studies 
Formation  of  AGEs  in  foods  is  a  complex  process  involving  several  reactions  and  many  end 
products. Only a few of them have been characterized and measured in foods. Some of these products 
have fluorescence properties. By taking advantage of this property, some studies have measured AGEs 
using chromatography methods while other studies have measured AGEs by immunohistochemical 
techniques [53,98]. There is as yet no agreement among the different groups studying dietary AGEs as 
to which is the best. Recently Uribarri et al. published a food database with approximately 500 food 
items with CML content using ELISA [49]. This database represents a great tool to asses CML content Nutrients 2010, 2  
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of the diet of larger populations. However, more extensive research with other methodology is needed 
to validate CML content of this database.  
Intervention studies on the implications of reducing dietary AGEs have been performed mainly in 
patients with renal disease or diabetes. A few studies exploring the short term effects (2–4 weeks) of 
reducing dietary AGEs in healthy subjects have been performed mainly in young population [99,100]. 
Long-term clinical studies with older individuals are needed to determine the health effects of dietary 
AGEs  on  this  population,  but  the  methodological  design  of  long-term  studies  represents  a  great 
challenge. One of the difficulties is achieving diets with different dietary AGEs content, but with 
similar content in other nutrients, such as heat-sensitive vitamins. Pouillart et al. demonstrated that 
diets with different dietary AGEs content but similar thiamine, vitamin E and other heat-sensitive 
vitamins content, are challenging but possible [101]. Future intervention studies addressing the impact 
of dietary AGEs will need to include diets with varying AGEs content, adequate content of all nutrients, 
as well as be attractive and tasteful to achieve high compliance during these long-term interventions.  
8. Conclusions  
Although the data are not conclusive, the convergence of data from diverse experimental studies 
suggests an important role of AGEs in healthy aging, as well as chronic disease morbidity. Certainly 
the data are supportive that endogenous AGEs are associated with declining organ functioning. It 
appears that dietary AGEs may also be related. There are no conclusive results about the damaging 
effect of Maillard products from foods, but it appears from several studies that Maillard products 
coming from foods rich in protein and fat are more damaging than Maillard products from bread crust, 
and  roasted  coffee.  Foods  rich  in  protein  and  fat  seem  to  have  a  higher  content  of  CML  and 
Methylglyoxal; in contrast, bread crust has lower content of these two AGEs. However, characterization 
of AGEs in food and biomarkers of these AGEs require additional research before reaching a conclusion.  
Although many promising pharmacologic anti-AGE therapies exist, their efficacy and safety are 
still under study. Research in this area is in the earliest phase, and a long time could pass before the 
U.S. Food and Drug Administration could approve a drug targeting AGE formation or modification. 
As of today, restriction of dietary intake of AGEs and exercise has been shown to safely reduce 
circulating AGEs, with further reduction in oxidative stress and inflammatory markers. More research 
is  needed  to  support  these  findings  and  to  incorporate  these  into  recommendations  for  the 
elderly population. 
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